Novavax (NVAX) Cash from Financing Activities (2010 - 2026)

Novavax's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $37.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 633.56% year-over-year to $37.7 million; the TTM figure through Mar 2026 stood at $72.5 million (down 70.73% YoY), while the FY2025 annual figure was $27.7 million, down 89.36% from the prior year.
• Cash from Financing Activities was $37.7 million for Q1 2026 at Novavax, up from -$6.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $258.2 million in Q2 2024 to a low of -$354.4 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged $38.6 million across 5 years, with a median of $5.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 321.67% in 2023, then surged 43854.64% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $191.4 million in 2022, then tumbled by 47.56% to $100.4 million in 2023, then sank by 103.41% to -$3.4 million in 2024, then tumbled by 92.99% to -$6.6 million in 2025, then surged by 670.49% to $37.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $37.7 million (Q1 2026), -$6.6 million (Q4 2025), and $42.4 million (Q3 2025), per Business Quant data.